The European Bank for induced pluripotent Stem Cells launches a second project phase

 

The European Bank for induced pluripotent Stem Cells - today announced the launch of a second project phase. EBiSC2 builds on the achievements of the European Bank for hiPSCs (EBiSC), giving academic and commercial researchers access to high quality hiPSCs from diverse disease and genetic backgrounds (cells.ebisc.org). CMAST - a leading consultancy and project management company in life sciences – is also involved in this project, in support of Janssen Pharmaceutica.

EBiSC2 will secure long-term access to well characterised and quality-controlled hiPSCs for academic and commercial researchers worldwide, continuing to support R&D activities such as disease modelling and drug discovery. Additional services such as bulk production of hiPSCs and delivery of pre-differentiated cell populations will be established to facilitate the use of hiPSC in research.

EBiSC2 aims to collaborate with other ongoing or future iPSC programmes in an effort to continue serving as a central hub for the collection, banking, quality control and distribution of hiPSC lines, resulting in secured access for the research community to assets generated with public funds within these projects. Building on EBiSC's established clinical network, EBiSC2 will also progress clinical engagement to support collection and appropriate management of disease-relevant patient data to support disease modelling and drug discovery activities.

For more details, please visit the CMAST website.

The EBiSC2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement No 821362. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Note

CMAST is a leading consultancy and project management company in life sciences.


With a team of more than 90 industry experts, CMAST provides support to pharma and life sciences companies, universities and research institutes.


The company offers consultancy, project management and tangible business solutions in the following areas:

  • Early stage innovation services
  • Funding services
  • Project & Portfolio Management
  • R&D process optimization
  • Multi-stakeholder collaborations
  • Regulatory compliance & quality
  • Health data analytics & visualization
  • Supply chain

CMAST is headquartered in Temse (Belgium) and has branches in Germany, Poland and the US. Since 2018, CMAST is working together closely with XPE Pharma & Science to connect life sciences businesses and talent in a fast-changing world. CMAST and XPE Pharma & Science are both part of the Modis Group, which gives the companies a global reach. More info on https://www.c-mast.com

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?